Medulloblastoma Recurrent
specificA molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.
5
Centers
1
Active Trials
—
Cancer Funding
Top Centers for Medulloblastoma Recurrent(5)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive High-Volume Research Center | 78.0 |
| 2 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive | 55.5 |
| 3 | NCI Comprehensive | 55.5 |
| 4 | University of Illinois Cancer CenterChicago, IL | 55.5 |
| 5 | University of Cincinnati Cancer CenterCincinnati, OH | 55.5 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →